Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × osimertinib × Clear all

Phase

Phase 1 8 Phase 1/2 2 Phase 3 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 NSCLC 3 Carcinoma 3 Neoplasm Metastasis 2 Lung Neoplasms 2 Stage IB-IIIA Non-small Cell Lung Carcinoma 1 Non-small Cell Carcinoma 1 Neoplasms 1 Neoplasm, Residual 1 NSCLC Patients With Brain Metastasis 1 Locally Advanced or Metastatic Non-squamous NSCLC 1 Locally Advanced or Metastatic EGFR T790M+ NSCLC 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Bronchial Neoplasms 1 Brain Neoplasms 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Capecitabine 12 Gemcitabine 11 Cyclophosphamide 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 6 Prednisone 6 Ondansetron 6 Morphine 6 Irinotecan 6 Drug Therapy 6 Doxorubicin 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5 Sodium Chloride 5 Panitumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05629234 2025-12-24

ROSY-T

AstraZeneca

Phase 3 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡